Sen. Ron Johnson said he spoke to FDA Commissioner Marty Makary about the agency’s handling of rare disease treatments.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

The exit of the FDA’s Vinay Prasad is being chalked up to a series of controversial decisions on rare disease drugs by the biologics center he directed. Read Lizzy Lawrence’s article on his upcoming ...

In the breakup between Dana-Farber Cancer Institute and Mass General Brigham, the sides have decided to go with conscious uncoupling rather than an acrimonious divorce.

AI scribe company Nabla aims to be much more by using tech from Yann LeCun's new startup AMI, which just raised $1 billion.

O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming to STAT, she worked at WNYC’s Radiolab and Scientific American, and her ...

For physician Vishal Khetpal, the legal battle between Hims & Hers and Novo Nordisk (which, by the way, was settled yesterday) is just one symptom of something much larger going on with American ...

As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front of the American people. In a one-minute ad, the direct-to-consumer health company ...

Ugur Sahin and Özlem Türeci, the couple who co-founded BioNTech, are leaving the Covid-19 vaccine maker to start a new, mRNA-focused firm.

The co-founders of the Covid-19 vaccine developer BioNTech plan to leave the biotech to start a new mRNA-focused company ...

The number of potential antimicrobial treatments being developed by the world’s largest drugmakers nosedived by 35% over the past five years, according to a new analysis.

Vertex said a drug it secured as part of a $4.9 billion acquisition successfully reduced by half a key marker of a kidney disease known as IgA nephropathy.